Eli Lilly and Company and Incyte Corporation announced that a drug used to treat a type of skin disease is doing well in a late-stage trial.
The BREEZE-AD7 trial is slated for completion this year. The Endpoints site noted that Delaware-based Incyte has stopped funding for development of the drug, but does receive royalties.
The Delaware company may be betting on a cream using its blockbuster drug Jakafi to treat the condition. That product is going through clinical trials.
The recent trial studied baricitinib, an oral JAK inhibitor, to treat moderate to severe atopic dermatitis in adults met its primary endpoint. Adding baricitinib to standard-of-care topical corticosteroids significantly improved disease severity.
BREEZE-AD7, conducted outside of the United States,is the third of five placebo-controlled trials in the Phase 3 program and recruited patients from Asia, Europe, South America, and Australia.
“Atopic dermatitis is a chronic, relapsing condition that can vary greatly from person to person, and yet there are few medicines to address the different signs and symptoms in each patient,” said Lotus Mallbris, vice president of immunology development at Lilly. “Today’s baricitinib results in combination therapy reveal important additional clinical information in a chronic disease where patients currently have limited oral treatment options.”
Baricitinib is approved for the treatment of adults with moderately to severely active rheumatoid arthritis in more than 60 countries, including the U.S., member states of the EU and Japan, and is marketed as Olumant.
The drug comes with a “black. box” warning label on side effects that limits sales, Endpoints noted.